Vor Biopharma Inc. (VOR)
After hours:
| Previous close | 1.8100 |
| Open | 1.7600 |
| Bid | 1.6700 x 100 |
| Ask | 1.7300 x 100 |
| Day's range | 1.6500 - 1.7850 |
| 52-week range | 1.6200 - 5.7000 |
| Volume | |
| Avg. volume | 345,211 |
| Market cap | 116.649M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.7500 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 14.69 |
GlobeNewswireVor Bio Reports First Quarter 2024 Financial Results and Provides Company Update
On-track for trem-cel and VCAR33ALLO clinical updates in the second half of 2024Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended March 31, 2024, and provided a business update. “We are pleased with the strong enthusiasm fro
- GlobeNewswire
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences: The Citizens JMP Life Sciences Conference Fireside Chat: Tuesday, May 14, 2024 at 11:00 am ET Location: New York, NY A live webcast and archived replay of the fireside chat will be available on the investors section of www.vorbio.com. H.C. Wainwright 2nd Annual BioConnect Investor C
- GlobeNewswire
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of May 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 31,750 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 47,625 shares of Vor Bio’s common stock to six newly hired employees. The foregoing stock op
